Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Gynecol Obstet Biol Reprod (Paris) ; 41(7): 631-7, 2012 Nov.
Article in French | MEDLINE | ID: mdl-22771075

ABSTRACT

OBJECTIVES: Calcium channel blockers are the most frequently used tocolytics as first-line in France, frequently intravenously (nicardipine [Loxen(®)]). We would like to compare the side effects of intravenous nicardipine and oral nifedipine. MATERIALS AND METHODS: We performed a restrospective study on two consecutive periods. On the first period (March 2007-September 2008), 110 patients received intravenous nicardipine for preterm labor, and 67 patients received oral nifedipine on the second period (October 2008-January 2010). Side effects were recorded. RESULTS: Patients in the nicardipine-treated group had significantly more side effects (31% versus 16% for nifedipine group, P=0.03). No-administration way related adverse events did not differ between the two groups (P=0.1). There was more low blood pressure in patients treated with nifedipine (P=0.03), but shorter hospital stay (5.4 days versus 7.9 days with nicardipine, P=0.05). CONCLUSION: Using nifedipine simplifies tocolysis administration, and decreases hospital stays without increasing the risk of prematurity.


Subject(s)
Calcium Channel Blockers/adverse effects , Nicardipine/adverse effects , Nifedipine/adverse effects , Obstetric Labor, Premature/drug therapy , Tocolytic Agents/adverse effects , Adult , Female , France , Humans , Nicardipine/administration & dosage , Nifedipine/administration & dosage , Pregnancy , Retrospective Studies
2.
Ann Fr Anesth Reanim ; 29(4): e59-68, 2010 Apr.
Article in French | MEDLINE | ID: mdl-20347561

ABSTRACT

Few studies establishing clear criteria for the medical interruption of a pregnancy complicated by PE are available today. Most of these studies are either retrospective or observational. When combining an analysis of the available literature together with the experts' opinions, one can propose the following set of criteria for therapeutic interruption of pregnancy in the setting of PE, which apply mainly for the severe forms of the disease. These criteria can be subdivided into maternal and fetal criteria. Maternal criteria are a severe uncontrollable HT, eclampsia, acute pulmonary edema, retro placental haematoma, oligura (<100 ml in 4 hours) resistant to appropriate fluid expansion, persistent signs of imminent eclampsia (headache or visual disturbances), persistent epigastric pain, HELLP syndrome, new-onset renal failure and a gestation time within the first 24 weeks. The fetal criteria are prolonged and variable fetal heart rate (FHR) decelerations, a short term variability in FHR <3 bpm, a Manning score < or =4 on two separate occasions, severe oligohydramnios, an estimated fetal weight below the 5(th) percentile beyond the 32(nd) week of amenorrhea and an inverted diastolic flow in the umbilical artery beyond the 32(nd) week of amenorrhea. In case of non-severe PE beyond the 36(th) week of amenorrhea, interruption of the pregnancy must be considered.


Subject(s)
Abortion, Therapeutic , Pre-Eclampsia/surgery , Adrenal Cortex Hormones/therapeutic use , Adult , Anti-Inflammatory Agents/therapeutic use , Clinical Trials as Topic , Eclampsia/diagnosis , Eclampsia/therapy , Female , Fetal Monitoring , Humans , Monitoring, Physiologic , Pregnancy , Prospective Studies , Randomized Controlled Trials as Topic , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...